BioSpace News Archive

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Wolfe Virtual Healthcare Conference on Thursday, November 19 at 11:25 a.m. ET.

Imago BioSciences, Inc., (“Imago”) a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced that interim data from its ongoing Phase 2b study evaluating bomedemstat (IMG-7289) for the treatment of myelofibrosis will be presented in an oral session during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually Dec. 5-8, 2020

Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, will host its second in a series of virtual seminars highlighting the latest data from its HPK1 program. The seminar, titled “Novel, Potent, Selective HPK1 Inhibitors Enhance Immune

– Magenta advanced its MGTA-145 mobilization program, with two Phase 2 trials to be initiated by end of 2020; the Company’s MGTA-117 conditioning program is on track to file an IND and generate clinical data in 2021; – Magenta announced appointment of Lisa M. Olson, Ph.D., as Head of Research and Chief Scientific Officer – – Magenta named co-recipient of a U19 grant from the National Institutes of Health as part of an interdisciplinary effort

-- Data demonstrate that patients enrolled in the GAIN Trial have baseline biomarkers consistent with Alzheimer’s disease and potential responders to atuzaginstat -- -- Press release issued in advance of CTAD presentation as an SEC exemption to the embargo policy, granted by the conference’s organizers --

Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the commercial launch of its Lumivascular products and completion of its first patient cases in Israel.

Halberd Corporation (OTC PINK: HALB ) reports its research team developed a second monoclonal antibody against Covid-19 SARS 2 disease antigens paving the way for development of a potentially more effective nasal spray. Additionally, Halberds continuing work on its new class of antibody doubles the performance capacity of a key functional parameter.

The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) during the high-risk 90-day period following a heart attack

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that on November 4, 2020 it entered into a privately negotiated exchange and purchase agreement (the “Agreement”) with a holder of its currently outstanding 4.50% Convertible Senior Notes due 2024 (the “Existing 2024 Notes”). Pursuant to the Agreement, in exchange for $64,842,000 aggregate principal amount of Existing 2024 Notes held by the holder (which is currently con

Seagen Announces Multiple ADCETRIS ® (Brentuximab Vedotin) Presentations at the Upcoming ASH Annual Meeting - Five-Year Update to be Presented from ADCETRIS Phase 3 ECHELON-1 and ECHELON-2 Clinical Trials - - Additional Data Analyses Highlight Activities Across Broad ADCETRIS Development Program -